⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836642 | 1.00 | — | — | |
| SCHEMBL2603677 | 1.00 | — | — | |
| SCHEMBL4539270 | 0.88 | ACACB (0.36) | — | |
| SCHEMBL16782377 | 0.88 | ACACB (0.36) | — | |
| SCHEMBL2077091 | 0.86 | KAT2B (0.41) | — | |
| Glutarate SCHEMBL17873211 | 0.86 | PDE4D (0.36) | — | |
| SCHEMBL22072511 | 0.86 | EPHX1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL27781343 | 0.84 | KAT2B (0.40) | — | |
| SCHEMBL27769437 | 0.83 | PDE4D (0.33) | — | |
| Cyclopropane SCHEMBL5316733 | 0.83 | KAT2B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-11548906-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2023-01-10 | — | — | US | disclosed |
| US-20200331946-A1 | PROCESSES FOR THE PREPARATION OF SGLT-2 INHIBITORS, INTERMEDIATES THEREOF | EMMENNAR PHARMA PRIVATE LIMITED, (IN) | 2020-10-22 | — | — | US | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| CN-110618208-A | Method for detecting content of (S) - (+) -3-hydroxytetrahydrofuran enantiomer | 威海迪素制药有限公司 | 2019-12-27 | — | — | CN | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180346502-A1 | Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2018-12-06 | — | — | US | disclosed |
| US-9796712-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-7608632-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608632-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-27 | — | — | US | disclosed |
| EP-1784393-B1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | TUNG ROGER D | 2008-11-27 | — | — | US | disclosed |
| US-20080293727-A1 | Novel sulfonamide inhibitors of aspartyl protease | TUNG ROGER D | 2008-11-27 | — | — | US | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321063-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2008002924-A2 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |